Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients

References

• Mohd Hanafiah K, Groeger J., Flaxman ADWiersma ST. Global epidemiology of hepatitis c virus infection: new estimates of age-specific antibody to hcv seroprevalence. Hepatology. 2013;57:1333–1342. DOI: 10.1002/hep.26141
   PubMed Web of Science ®Google Scholar
• Gaetano JN. Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir. Drug Healthc Patient Saf. 2014;6:37–45.
   PubMedGoogle Scholar
• Roberts SK, Weltman MD, Crawford DH, et al. Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology. 2009;50:1045–1055.
   PubMed Web of Science ®Google Scholar
• Cheng WS, Roberts SK, McCaughan G, et al. virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol. 2010;53:616–623.
   PubMed Web of Science ®Google Scholar
• Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344:495–500.
   PubMed Web of Science ®Google Scholar
• Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey for the group of epidemiology of the French association for the study of the liver (AFEF). Hepatology. 2000;32:477–481.
   PubMed Web of Science ®Google Scholar
• Lackner C, Struber G, Liegl B, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology. 2005;41:1376–1382.
   PubMed Web of Science ®Google Scholar
• Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705–1713.
   PubMed Web of Science ®Google Scholar
• Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343–350.
   PubMed Web of Science ®Google Scholar
• Rosenberg WMC, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127:1704–1713.
   PubMed Web of Science ®Google Scholar
• Elsharkawy A, Fouad R, El Akel W, et al. Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt. Aliment Pharmacol Ther. 2017;45(5):681–687.
   PubMed Web of Science ®Google Scholar
• Yosry A, Fouad R, Alem A, et al. Fibroscan, APRI, FIB4, and GUCI: role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection. Arab J Gastroenterol. 2016;17(2):78–83
   PubMed Web of Science ®Google Scholar
• Arias A, Aguilera A, Soriano V, et al. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials. Antivir Ther. 2017;22(4):307–312.
   PubMed Web of Science ®Google Scholar
• Neukam K, Morano-Amado LE, Rivero-Juárez A, et al. Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients. Eur J Clin Microbiol Infect Dis. 2017 May;36(5):853–861.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Matusow G, DeJesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology. 2016;64:360–369.
   PubMed Web of Science ®Google Scholar
• EASL. Recommendations on treatment of hepatitis C. J Hepatol. 2015;63:199–236.
   PubMed Web of Science ®Google Scholar
• Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis inpatients with HIV/HCV co-infection. Hepatology. 2006;43:1317–1325.
   PubMed Web of Science ®Google Scholar
• Dietrich CF, Bamber J, Berzigotti A, et al. EFSUMB guidelines and recommendations on the clinical use of liver ultrasound elastography, update 2017 (Long Version). Ultraschall Med. 2017 Aug;38(4):e16–e47.
   PubMed Web of Science ®Google Scholar
• The Polaris Observatory. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–176.
   PubMed Web of Science ®Google Scholar
• van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–2593.
   PubMed Web of Science ®Google Scholar
• Estes C, Abdel-Kareem M, Abdel-Razek W, et al. Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies. Aliment Pharmacol Ther. 2015;42(6):696–706.
   PubMed Web of Science ®Google Scholar
• Gower E, Estes CC, Hindman S, et al. Global epidemiology and genotype distribution of the hepatitis C virus. J Hepatol. 2014;61:S45–57.
   PubMed Web of Science ®Google Scholar
• Eletreby R, Elakel W, Said M, et al. Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients. Liver Int. 2017;37(4):543-541.
   Web of Science ®Google Scholar
• EASL. Recommendations on treatment of hepatitis C 2016. J Hepatol. 2017 Jan;66(1):153–194.
   PubMedGoogle Scholar
• Lai MM. Hepatitis C virus proteins: direct link to hepatic oxidative stress, steatosis, carcinogenesis and more. Gastroenterology. 2002;122:568–571.
   PubMed Web of Science ®Google Scholar
• Elsharkawy A, Abdel Alem S, Fouad R, et al. Changes in liver stiffness measurements and Fibrosis scores following Sofosbuvir based treatment regimens without Interferon. J Gastroenterol Hepatol. 2017 Sep;32(9):1624–1630.
   PubMed Web of Science ®Google Scholar
• Bachofner JA, Valli PV, Kröger A, et al. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int. 2017 Mar;37(3):369–376.
   PubMed Web of Science ®Google Scholar
• Lee SS, Heathcote EJ, Reddy KR, et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol. 2002;37:500–506.
   PubMed Web of Science ®Google Scholar
• Reiberger T, Rutter K, Ferlitsch A, et al. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol. 2011;9:602–608.
   PubMed Web of Science ®Google Scholar
• Backus LI, Belperio PS, Shahoumian TA, et al. Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients. Antivir Ther. 2017;22(6):481–493.
   PubMed Web of Science ®Google Scholar
• Akuta N, Sezaki H, Suzuki F, et al. Retreatment efficacy and predictors of ledipasvir plus Sofosbuvir to HCV genotype 1 in Japan. J Med Virol. 2017;89:284–290.
   PubMed Web of Science ®Google Scholar
• AASLD/IDSA. Recommendations for testing, management, and treating hepatitis C. Retreatment of persons in whom prior therapy has failed. [cited 2015 Jun 25]. Avaialable from: http://www.hcvguidelines.orgon03/17/2014
   Google Scholar
• Poordad F, Bronowicki JP, Gordon SC, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology. 2012;143:608–618.
   PubMed Web of Science ®Google Scholar
• Butt AA, Yan P, Marks K, et al.; ERCHIVES Study Team. Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES. Aliment Pharmacol Ther. 2016 Oct; 44(7):728–737.
   PubMed Web of Science ®Google Scholar
• Bourliere M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15:397–404.
   PubMed Web of Science ®Google Scholar
• Lu M, Wu KH, Li J, et al. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure. J Viral Hepat. 2019 Jun 13. DOI:10.1111/jvh.13162.
   Web of Science ®Google Scholar